|View printer-friendly version|
|October 18, 2005 11:48 a.m.|
|Teva and Wyeth Announce Settlement of Effexor Xr® Litigation|
Jerusalem, Israel, October 18, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Wyeth (NYSE:WYE) today announced that they have reached agreement on the principal terms of a settlement of the U.S. patent infringement litigation pertaining to Teva's generic version of Wyeth's Effexor XR® antidepressant pending in the United States District Court for the District of New Jersey. The parties are currently drafting definitive agreements and intend to submit the settlement agreements to the Federal Trade Commission ("FTC"). The terms of the settlement are confidential and are subject to a number of conditions, including review of the settlement by the FTC and the approval of the District Court.